Viracta Therapeutics, Inc. - Multiplikator EV/Sales VIRX

Logo perusahaan publik Viracta Therapeutics (VIRX)

Viracta Therapeutics is developing therapies for Epstein-Barr virus-associated lymphomas, systematically preparing its lead drug for registration. The enterprise value-to-revenue ratio reflects the market's reaction to these achievements, with serving as the final level marker. Stability is provided by a proprietary enzyme activation platform and strategic partnerships, while the implementation of "green chemistry" minimizes the toxicity of production waste.

Nilai perusahaan marang pendapatan Viracta (VIRX): kanggo periode 04.07.2022 - 20.11.2026

Rincian metrik keuangan lan pasar Viracta Therapeutics, Inc. (VIRX)

Produk seri viracta.com

This ratio compares the total enterprise value to sales volume, excluding the impact of leverage to determine the actual market revaluation of operating flows. Analyzing the dynamics of the EV/Revenue multiple allows for stress-testing the resilience of Viracta Therapeutics (VIRX) assets, confirming that the uniqueness of the Kick & Kill platform and patent protection create a fundamental barrier against capitalization degradation.

Analisis pesaing Viracta Therapeutics

Rasio nilai perusahaan marang dodolan BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Rasio nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Revolution Medicines Inc (RVMD)|Rasio nilai perusahaan marang pendapatan Ascentage Pharma Group|Rasio nilai perusahaan marang pendapatan CGON (CG Oncology Corp)|Rasio nilai perusahaan marang pendapatan UroGen Pharma (URGN)|Multiplikator EV/Sales Bicara Therapeutics (BCAX)|Multiplikator EV/Sales PSNL (personalis.com)|Nilai bisnis marang pendapatan ERAS|DCTH: Nilai perusahaan marang pendapatan|YmAbs - Koefisien nilai perusahaan marang pendapatan|aurabiosciences.com (AURA) - Rasio nilai perusahaan marang pendapatan|Candel Therapeutics Inc. - Nilai bisnis marang pendapatan|Rasio nilai perusahaan marang pendapatan Accuray Inc.|Multiplikator nilai perusahaan marang pendapatan SELLAS Life Sciences Group SLS|Multiplikator EV/Sales ACTU|CTOR - Multiplikator nilai perusahaan marang pendapatan|Multiplikator EV/Sales HURA (TuHURA Biosciences, Inc.)|Nilai bisnis marang pendapatan TARA|FATE: Nilai perusahaan marang pendapatan|WHWK (aadibio.com) - Rasio nilai perusahaan marang pendapatan|TCRX (TScan Therapeutics, Inc.) - Nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Multiplikator EV/Sales|CVM (CEL-SCI Corporation) - Koefisien nilai perusahaan marang pendapatan|Multiplikator EV/Sales OSTX|Multiplikator EV/Sales Radiopharm Theranostics Ltd (RADX)|Multiplikator EV/Sales ARTV (Artiva Biotherapeutics)|Multiplikator EV/Sales Adlai Nortye Ltd. ANL|Veru Inc - Multiplikator EV/Sales|Rasio total nilai perusahaan marang pendapatan Tempest Therapeutics TPST|XLO: Multiplikator EV/Sales|Enochian BioSciences (RENB) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan MURA|Kairos Pharma Ltd - Nilai perusahaan marang volume dodolan|Multiplikator EV/Sales OKUR|CytoMed Therapeutics Limited (GDTC) - Rasio nilai perusahaan marang dodolan|Multiplikator EV/Sales CRIS (Curis, Inc.)|APLM: Rasio nilai perusahaan marang pendapatan|Tharimmune Corporation - Multiplikator EV/Sales|ADVB: Rasio nilai perusahaan marang pendapatan|GNPX: Multiplikator EV/Sales|CLDI (Calidi Biotherapeutics Inc.) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan Sunshine Biopharma, Inc.|Multiplikator EV/Sales xeneticbio.com|Rasio nilai perusahaan marang pendapatan Salarius (SLRX)|Nilai perusahaan marang pendapatan Purple Biotech PPBT|Rasio nilai perusahaan marang pendapatan American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Multiplikator nilai perusahaan marang pendapatan|Checkpoint Therapeutics Inc. - Multiplikator EV/Sales|Nilai bisnis marang pendapatan ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Nilai perusahaan marang pendapatan|Ikena Oncology, Inc. - Nilai bisnis marang pendapatan|Nilai perusahaan marang pendapatan NTBL|MOR: Nilai bisnis marang pendapatan|Multiplikator EV/Sales NAYA|Ascentage Pharma - Rasio nilai perusahaan marang pendapatan